About the Webinar
Adoptive immunotherapy with T cells genetically modified to recognize tumors is rapidly becoming a promising and evolving treatment option. Antitumor activity, however, can be dampened by both limited co-stimulation and triggering of immunoregulatory checkpoints that attenuate T-cell responses. In this webinar, Dr. Shannon Oda, a research associate in the group of Dr. Phillip Greenberg (Fred Hutchinson Cancer Research Center), will talk about development of a CD200R-based immunomodulatory fusion protein (IFP) to improve anti-tumor T cell function and significantly enhance survival in a model of AML.
About the Presenter
Dr. Shannon Oda received a bachelor’s degree in Biology from Linfield College in 2004 and a Ph.D. in Immunology from the University of Colorado Anschutz Medical Campus in 2013. She has received several awards, including the Evergreen Fund Award and the LLS Career Development Program Special Fellow Award, and has been invited to give talks internationally. Dr. Oda joined the Fred Hutchinson Cancer Research Center in 2013, where she is a research associate of the Immunology Program in the Clinical Research Division. Her research focuses on improving T cell immunotherapy, which uses immune cells to target and destroy cancer cells. She has identified several obstacles that inhibit immune cells from effectively eradicating tumor and she is inventing new ways to engineer T cells to overcome these obstacles and improve immunotherapy of hematological and solid tumors.